Alzheimer's Disease Treatment Pipeline Remains Large Despite 95% Attrition Rate, Says GBI Research

• Alzheimer’s Disease (AD) treatment pipeline is relatively large with 583 active drugs, implying a high level of commercial interest
• Small molecule drugs account for around 65% of developmental programs in AD treatment pipeline, while biologics represent 26%, says report

While drug candidates for Alzheimer’s Disease (AD) fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research.

The company’s latest report^* states that 77% of AD pipeline drugs are in early stages of development, such as the discovery and Preclinical phases, whereas therapeutics in Phase III development occupy only 3% of the overall pipeline, reflecting a high level of attrition in late-stage trials.

Analysis of a large number of clinical trials conducted in the AD market since 2006 yielded an extremely high failure rate across all phases of development: 44% for Phase I, 69% for Phase II and 76% for Phase III, with the latter having almost three times the rate of failure compared with the pharmaceutical industry as a whole.

GBI Research says that the overall attrition rate across all phases is 95%, which further highlights that AD is a very high-risk indication for drug development. In light of these findings, the size of the AD developmental pipeline is surprising, but also indicative of the considerable unmet need and substantial commercial opportunities for strong products.

The report notes that the overall AD pipeline is still very much dominated by small molecule drugs, which account for approximately 65% of developmental programs, while biologics represent 26%. A further breakdown of biological therapies shows that most of these are monoclonal antibodies (mAbs), peptides and vaccines.

The diversity of molecule types is most prominent among Preclinical programs, but skews towards small molecules in late-stage programs. Indeed, 12 of the 15 Phase III therapies are small molecules, while there are only two mAbs, Gantenerumab and Solanezumab, and one protein product.

However, GBI Research believes that the pipeline holds some degree of promise, as companies are reacting to the continuing failures of drugs with popular targets by favoring novel mechanisms of action, such as tau, mitochondrial components, and insulin- and calcium-signaling targets, which could yield a greater level of success.

This report provides a comprehensive review of the Alzheimer’s Disease (AD) treatment pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target. It includes an assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, and of the licensing and co-development deal landscape for AD therapies.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

About GBI Research
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

^*Frontier Pharma: Alzheimer’s Disease - Identifying and Commercializing First-in-Class Innovation